Zura Bio Limited (NASDAQ:ZURA) Stock Rated “Moderate Buy” by Wall Street Brokerages

Zura Bio Limited (NASDAQ:ZURA) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $17.00.

A number of equities analysts recently commented on ZURA shares. Wall Street Zen raised shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. William Blair initiated coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating for the company. Wedbush raised their price target on shares of Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, October 2nd. Finally, Guggenheim lifted their price objective on shares of Zura Bio from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of ZURA. Montanova Capital LLC increased its position in shares of Zura Bio by 4.1% during the second quarter. Montanova Capital LLC now owns 9,443,001 shares of the company’s stock worth $55,714,000 after purchasing an additional 376,000 shares in the last quarter. Siren L.L.C. grew its stake in Zura Bio by 187.3% during the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock worth $22,222,000 after buying an additional 2,434,866 shares during the last quarter. Commodore Capital LP acquired a new stake in Zura Bio in the first quarter worth about $19,338,000. Affinity Asset Advisors LLC increased its stake in Zura Bio by 41.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,564,303 shares of the company’s stock valued at $15,258,000 after purchasing an additional 750,632 shares in the last quarter. Finally, EcoR1 Capital LLC purchased a new stake in shares of Zura Bio during the first quarter valued at $7,019,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Stock Down 3.1%

ZURA opened at $4.00 on Tuesday. Zura Bio has a 52 week low of $3.15 and a 52 week high of $7.44. The firm has a 50-day simple moving average of $5.19 and a two-hundred day simple moving average of $5.04. The company has a market capitalization of $383.32 million, a PE ratio of -3.54 and a beta of 0.01.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. As a group, sell-side analysts expect that Zura Bio will post -0.81 earnings per share for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on developing medicines for chronic immune-mediated diseases. The company’s research programs are designed to address conditions in which abnormal immune responses contribute to inflammation and tissue damage.

Zura Bio is advancing a pipeline of investigational antibody-based therapies for diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and systemic sclerosis. Its programs target biological pathways involved in inflammation, with the goal of developing treatments for patients who may not respond adequately to existing therapies.